3SOF

feedback is appreciated

Profile:
Novacea, Inc., a development stage biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer in the United States. Its lead product candidates include DN-101, which is in a Phase III clinical trial for the treatment of androgen-independent prostate cancer; vinorelbine oral, which would be used for the treatment of breast or lung cancer; and AQ4N, which would be used for the treatment of solid tumors.

Analysts:
Novacea rises on positive coverage start
Monday , June 19, 2006 12:36 ET

By Staff Reporter

NEW YORK, Jun 19, 2006 (XFN-ASIA via COMTEX) -- Shares of Novacea Inc. rose Monday after a group of analysts initiated positive coverage on the biotech drug developer based on its experimental cancer treatments.

Novacea shares rose 41 cents, or 6.6 percent, to $6.61 in late morning trading on the Nasdaq. The stock began trading on May 11 priced at $6.50, and have traded between $6.01 and $7.37.

Investment firms Bear Stearns, Pacific Growth Equities, Cowen & Co., and HSBC all initiated coverage of the South San Francisco, Calif.-based company with Buy-grade ratings.

Analysts all pointed to mid-stage clinical data showing DN-101, when used along with Sanofi-Aventis SA's Taxotere, significantly lowering the risk of death and adverse events in advanced-stage prostate cancer patients.

In a note, Bear Stearns analyst Akhtar Samad fixed a target price of $10 and said that Novacea set itself apart from other small biotechs by conducting a large, controlled mid-stage clinical trial on the drug with Taxotere versus Taxotere alone. The analyst called the 49 percent improvement in survival time with both drugs "impressive," and forecast U.S. sales to peak at about $180 million in 2012.

Pacific Growth Equities analyst Gregory Wade took an even more optimistic view of the drug and set his sales forecast nearly four times higher. Wade estimates DN-101 sales of $647 million by 2011, with those approaching $1 billion by 2015.

Cowen & Co. analyst Eric Schmidt, who rates the company an "Outperform," said the treatment could transform the prostate cancer market.

HSBC analyst Gene Mack set a $12 price target, and estimated DN-101 would generate $149 million in first year sales after a 2010 launch with sales peaking between $540 million and $720 million.

Novacea is also developing a treatment for breast and lung cancer called vinorelbine, and a brain cancer treatment called AQ4N.

chart and slides:

WOW 
Novacea shares soar on positive coverage initiation
By Carolyn Pritchard, MarketWatch
Last Update: 5:05 PM ET Jun 19, 2006


SAN FRANCISCO (MarketWatch) -- Novacea Inc. shares rocketed to a fresh 52-week high Monday after a number of analysts initiated coverage on the company, citing a positive outlook for the market potential of its prostate cancer therapy.
Shares of the South San Francisco, Calif., drug developer (NOVC
novacea inc com  NOVC ) soared $2.23, or 36.1%, to end the session at $8.40. Intraday, the stock hit $8.69, far outpacing its previous year high of $7.37 for the year.
Pacific Growth Equities analyst Gregory Wade started coverage of Novacea with a buy rating, saying he believes the company's lead drug candidate, DN-101, could see U.S. sales approaching $1 billion when used as a treatment of androgen independent prostate cancer.
Data for a controlled Phase II study of DN-101, a super-potent form of Vitamin D, showed a statistically significant improvement in the survival of patients with advanced prostate cancer when used in combination with Sanofi-Aventis SA's (SNY
sanofi aventis sponsored adr
Sponsored by:
SNY ) Taxotere as opposed to using Taxotere alone, noted Bear Stearns analyst Akhtar Samad.
Moreover, fewer adverse events were observed in patients taking the DN-101- Taxotere treatment compared with a placebo group.
"This distinguishes Novacea from most newly public stage-cancer biotechs that have not run large controlled Phase II trials," Samad wote in a note to investors. He started coverage of the company at outperform with a $10 price target. Data from a Phase III trial that's curently underway are expected late in 2008.

Novacea has two other notable cancer drugs in its pipeline: an oral version of vinorelbine, for which late-stage trials in patients with metastatic breast cancer are expected to start in the second half of fiscal 2006; and AQ4NA, which induces cell death in tumors in low-oxygen environemnts and is seen entering Phase II/III trials during the second half of fiscal 2006 in patients with brain cancer.
Eric Schmidt of Cowen & Co. believes that although Novacea's a relative newcomer and has yet to establish a signficant track record with investors, "its programs compare favorably to those of other Phase II- and Phase III-stage cancer companies."
DN-101 in particular, Schmidt wrote, could "transform the prostate cancer market."
Schmidt initiated coverage of Novacea with an outperform rating. 



(not pulled the buy trigger yesterday  )

cheers
Oliver

again 

NOVC: Volume Spike; 17% > 20-adsv, Stock +16.43%
Tuesday , June 20, 2006 10:45 ET

This is the 1st VOLUME alert for NOVC in the past 7 calendar days.

Trading for Novacea, Incorporated (NASDAQ NM: NOVC) has been heavier than usual in today's session. By 10:45 ET, the stock had already traded 124,000 shares via 216 trades. The cumulative volume is 17.06% above its 20-day average of 105,928. Normally the stock experiences around 90 individual trades per session.

So far, today's volume surge has caused a net rise in NOVC's stock price. At the time of this alert, the stock was trading at $9.780, up $1.380 (+16.43%).

One month ago, the Company's shares closed at $6.500. The price has gained more than 50 percent since then.

Over the last 10 trading session NOVC has traded in a range between $6.010 and $8.688 and is currently trading 12.57% above its 52-week high of $8.688 set on June 19,2006 and 62.73% above its 52-week low of $6.010 from June 14,2006.

In the previous 3 sessions, NOVC trading has displayed a mixed trend. Closing results have been as follows:

June 19, 2006 --- closed at $8.400 up $2.228 (+36.10%) on 71,210 shares
June 16, 2006 --- closed at $6.172 down $0.168 (-2.65%) on 700 shares
June 15, 2006 --- closed at $6.340 down $0.210 (-3.21%) on 1,000 shares

wow 

Form 10Q Report:
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=4238139

new 53 week high 

TA feddback would be appreciated 

Anyone else pick up on NOVC?

They were up huge yesterday on the announcement of a deal with Schering-Plough:
http://biz.yahoo.com/iw/070530/0259129.html

which potentially means about $500M in milestone payments for their PC drug Asentar.  Some have been speculating that Asentar is more significant than DNDN's Provenge in the AIPC drug space, but this kind of tie up definitely signals Schering-Plough's confidence in this drug's potential.  I haven't had time to do more thorough research on it, but I liked the 50% retracement on the initial move, back down to 12.65, and the strong end to the day after basing at this level.  I'm long here at 13.40.

Like the action today. seems like we should have seen more tankage given the overall market destruction the past 2 days... so I went long 1500 shares at 11.15

we'll see tomorrow.
g

had loaded more at 10.42, then sold it all at 10.81 for a 200$ loss...

now long again at 10.17 for a bounce

g

This looks ready for a STEPS reversal soon, I went ahead and nibbled today at 9.75.

STEPS reversal seems to be taking shape today, trading at 10.03 now

News out today, Shering putting more money into NOVC, NOVC up 13% now to $10.80. 
---------------------------------------
Agreement for Asentar

  SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 07/11/07 --

   Novacea, Inc. (NASDAQ: NOVC), today announced that it has received $60
million from Schering-Plough Corporation (NYSE: SGP) under the terms of the
previously announced worldwide development and commercialization agreement for
Asentar(TM) (DN-101).  The payment from the closing of this transaction follows
the early terminationby the United States Federal Trade Commission of the
waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

  Under the terms of the development and commercialization agreement,
Novaceareceived an upfront payment of $60 million, including $35 million as
reimbursement for past research and development expenses and a license fee of
$25 million.  In addition, pursuant to a related stock purchase agreement,
Schering-Plough purchased $12 million of Novacea common stock. The development
and commercialization agreement provides Novacea with potential pre-commercial
milestone payments of up to $380 million, and royalties on worldwide sales of
Asentar based on tiered royalty percentage rates.

  Schering-Plough also will be responsible for all forward development costs in
exploring indications for earlier stages of prostate cancer, such as
androgen-dependent prostate cancer and adjuvant therapy and will lead all
global commercialization efforts for Asentar.  Novacea will provide
medicalsupport to Schering-Plough's commercial operations for Asentar in the
United States, including deployment of their Medical Science Liaisons, which
will be funded by Schering-Plough.

  About Asentar

  Asentar is currently being developed as an oral treatment in combination with
Taxotere(R)(docetaxel) for the treatment of AIPC. Prostate cancer is the second
leading cause of cancer death in men with approximately 232,000 new cases and
30,000 deaths in the U.S. in 2005. AIPC is an advanced disease state of
prostate cancer. Based on results of Novacea's completed Phase 2 clinical
trial, known as ASCENT, the use of weekly Asentar in combination with weekly
Taxotere may provide AIPC patients with an innovative cancer therapy that may
prolong survival with the potential in reducing some of the toxicities and
complications normally associated with chemotherapy. Novacea is now evaluating
the benefits of Asentar in a 900-patient Phase 3 trial, known as ASCENT-2,
which uses overall survival as the primary endpoint and compares weekly Asentar
plus Taxotere to the current standard of care in the treatment of AIPC.

  About Novacea

  Novacea, Inc. is a biopharmaceutical company focused on in-licensing,
developing and commercializing novel cancer therapies. Novacea has two novel
oncology product candidates in clinical trials. Asentar(TM), which is partnered
with Schering-Plough Corporation, currently is in a Phase 3 clinical trial for
androgen-independent prostate cancer (AIPC). Novacea's second product
candidate, AQ4N, is a hypoxia-activated prodrug that is currently in a Phase
1b/2a clinical trial in glioblastoma multiforme.  More information on any of
Novacea's trials can be found at www.ClinicalTrials.gov.

  Note: Except for the historical information contained herein, the matters set
forth in this press release, including statements as to financial guidance,
development, clinical studies, regulatory review and approval, and
commercialization of products, are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements speak only as of the date the
statements are made and are based on information available at the time those
statements are made and/or management's good faith belief as of that time with
respect to future events. You should not put undue reliance on any
forward-looking statements. Important factors that could cause actual
performance and results to differ materially from the forward-looking
statements we make include: early stage of development; the focus, conduct,
enrollment and timing of our clinical trials; regulatory review and approval of
product candidates; commercialization of products; developments relating to our
licensing and collaboration agreements; market acceptance of products; funding
requirements; intellectual property protection for our product candidates;
competing products and other risks detailed from time to time under the heading
"Risk Factors" in our most recent Quarterly Report on Form 10-Q or Annual
Report on Form 10-K, as may be updated from time to time by our future filings
under the Securities Exchange Act. If one or more of these risks or
uncertainties materialize, or if any underlying assumptions prove incorrect,
our actual performance or results may vary materially from any future
performance or results expressed or implied by these forward-looking
statements. We assume no obligation to update forward-looking statements to
reflect actual performance or results, changes in assumptions or changes in
other factors affecting forward-looking information, except to the extent
required by applicable securities laws.

  Novacea is a registered trademark of Novacea, Inc., and Asentar is a
trademark of Novacea, Inc. All other trademarks are property of their
respective owners.

     Media: Paul Laland 650-228-1811 [email protected] Investors: Nina Ferrari
415.264.8796 [email protected]

  (END) Dow Jones Newswires

  07-11-07 0832ET

08:32 071107